Veracyte (VCYT) investor relations material

Strategic focus and portfolio management

• Portfolio streamlined to focus on high-ROI products, primarily Afirma and Decipher, with other products trimmed or deprioritized.

• Emphasis on optimizing revenue growth and maintaining a 25% Adjusted EBITDA margin through 2026, with incremental investments directed at pipeline development.

• Launches planned for Prosigna in summer and first MRD platform demonstration in muscle-invasive bladder cancer.

• Investments in data infrastructure and AI to leverage large-scale real-world evidence and genomic databases.

• Reinvestment of gross margin gains into new growth drivers, including MRD and Prosigna.

Decipher and Afirma product performance

• Decipher continues to deliver over 20% volume growth, with strong evidence base and guideline inclusion supporting market share gains.

• Penetration across the risk continuum and new prescriber growth are key drivers, with 18% growth in new doctors in Q4.

• Decipher ASP expected to grow 300-500 basis points over five years, with 215 million covered lives and strong reimbursement rates.

• Afirma holds 52% market share, growing above market despite high penetration, with share gains and new classifier signatures as future drivers.

• Transition to NovaSeq X for Afirma reduces sequencing costs and RNA input, improving gross margins and result rates.

Competitive landscape and innovation

• Competitive landscape for Decipher remains stable, with recent competitor growth attributed to easy comps.

• Digital pathology and AI initiatives are complementary to core tests, enhancing clinical value but not replacing existing classifiers.

• GRID platform fosters KOL engagement and academic traction, indirectly supporting share gains but not directly driving revenue.

• Afirma ASP is already best-in-class, with future gains expected to be incremental and driven by normalization of recent headwinds.